Tealwood Asset Management Inc. Has $2.53 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tealwood Asset Management Inc. raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 52,813 shares of the biopharmaceutical company’s stock after buying an additional 8,694 shares during the quarter. Halozyme Therapeutics makes up about 1.0% of Tealwood Asset Management Inc.’s investment portfolio, making the stock its 28th biggest holding. Tealwood Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $2,525,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fiduciary Alliance LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at about $398,000. First Hawaiian Bank lifted its position in Halozyme Therapeutics by 56.2% during the 4th quarter. First Hawaiian Bank now owns 57,550 shares of the biopharmaceutical company’s stock valued at $2,751,000 after purchasing an additional 20,700 shares during the period. Oliver Luxxe Assets LLC boosted its stake in shares of Halozyme Therapeutics by 5.6% in the 4th quarter. Oliver Luxxe Assets LLC now owns 29,325 shares of the biopharmaceutical company’s stock valued at $1,402,000 after purchasing an additional 1,555 shares during the last quarter. Everence Capital Management Inc. acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $244,000. Finally, Retirement Systems of Alabama raised its stake in shares of Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after buying an additional 74,173 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $54.14 on Tuesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock has a market cap of $6.89 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 0.44 and a beta of 1.24. The business has a 50 day simple moving average of $50.14 and a 200 day simple moving average of $54.03. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on HALO shares. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday. JMP Securities lifted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright upped their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.